We are pleased to share with you the most updated news about our SARS-CoV-2 Antigen Rapid Test: Market performance follow-up studies have confirmed the safety and effectiveness of Lepu SARS-CoV-2 Antigen Rapid test.
To continuously track and verify the performance of SARS-CoV-2 Antigen Rapid test, LEPU Medical Technology has conducted several post market performance follow-up studies in Germany after obtaining the approval of BfArM for self-testing.
The post market performance follow-up studies include the performance for layman and professionals respectively. The diagnostic sensitivity was 91.30%, and the specificity was 100% in the study done by Biomex in April 2021. The diagnostic sensitivity was 95.90%, and the specificity was 100% in the study done by Biomex in June 2021. The test results were both acceptable for layman and professionals.
Lepu will constantly deliver high-quality and innovative products to keep addressing the global medical needs. Please feel free to let me know if you have any questions. Thanks!
Follow us on social media
* Click download to get full reports